Intrahepatic Cholestasis of Pregnancy: A Systematic Review of Diagnostic Approaches, Evidence-Based Management Algorithms, Maternal–Fetal Outcomes, and Emerging Therapeutic Directions
Aim: To summarize current evidence on the diagnosis and management of intrahepatic cholestasis of pregnancy (ICP), focusing on diagnostic biomarkers, pharmacological treatment, fetal surveillance, delivery planning, maternal–fetal outcomes, and emerging therapeutic approaches. Materials and Methods: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Scopus, Web of Science, and SinoMed (Chinese Biomedical Literature Service System), were searched for relevant publications published between January 2016 and September 2026. Forty studies meeting the eligibility criteria were included in the final qualitative synthesis. The evidence was evaluated across diagnostic biomarkers, pharmacological interventions, fetal surveillance, delivery planning, and emerging therapeutic approaches. Results: Serum total bile acid concentrations remain central to the diagnosis and risk stratification of ICP, while maternal clinical characteristics, liver function tests, and gestational age at onset contribute to the overall assessment. Ursodeoxycholic acid (UDCA) remains the principal pharmacological treatment for maternal symptoms and biochemical abnormalities; however, evidence for its effect on major adverse perinatal outcomes remains limited. Maternal–fetal risk assessment, serial evaluation of bile acid concentrations, individualized fetal surveillance, and appropriately timed delivery are essential components of management. Emerging approaches include improved biomarker-based risk stratification and the investigation of alternative therapeutic targets. Conclusion: The management of ICP requires an individualized, risk-based approach integrating biochemical assessment, maternal symptom control, and gestational-age-specific obstetric planning. Serum bile acid concentrations remain central to evaluating fetal risk and guiding clinical decisions. Further prospective studies are needed to validate emerging biomarkers, establish the comparative effectiveness of therapeutic strategies, and refine management algorithms to improve maternal and perinatal outcomes.
Authors
- Petar N. Ignatov (ORCID: https://orcid.org/0000-0003-1656-5316)
- Zlatko Kirovakov (ORCID: https://orcid.org/0009-0003-7643-5879)
- Boris Stoilov (ORCID: https://orcid.org/0000-0001-5221-3815)
- Teodora Kirovakova
Institutions
- Medical University Plovdiv (BG)
- Medical University of Sofia (BG)
- Prof. Assen Zlatarov University (BG)
Publication Details
- Journal
- Fetal Medicine Obstetrics and Gynecology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.70926/fmog/1/2026.3.1.0001.cho
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00